-

Cosette Pharmaceuticals Launches Dapsone 5% Gel, AB-Rated to Aczone® 5%

Launch continues the expansion of Cosette’s generic portfolio and global partnership strategy

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc. (“Cosette”), in partnership with SeegPharm SA (Lugano, Switzerland), is proud to announce the launch of Dapsone 5% Gel (NDC # 0713-0886-18, 0713-0886-60), an important and affordable alternative for patients to treat acne.

Apurva Saraf, President and CEO of Cosette, stated “This launch further validates Cosette’s ability to successfully partner globally and launch affordable, high-quality drugs. We are staying true to our motto ‘Innovating Every Day’ and are committed to being a trusted partner of choice, while continuing the important work of serving US patients and prescribers through R&D and Global Business Development partnerships.”

According to IQVIA, US annual sales for the 12 months ended December 2022 for Dapsone 5% Gel USP were approximately $20 million.

See the Full Prescribing Information and Instructions for Use for Dapsone 5% Gel. www.dailymed.com

Aczone® is registered trademark of Almirall, LLC.

About Cosette Pharmaceuticals: Cosette Pharmaceuticals, Inc. (“Cosette”) is a US-based, fully integrated pharmaceutical company with capabilities in product development, manufacturing, and commercial operations. Cosette has a fast-growing portfolio of branded pharmaceuticals consisting of products in the cardiology, women’s health and migraine markets. Cosette has a long history in quality manufacturing of complex dosage forms including topical creams, ointments, oral liquids/solutions and suppositories, which has led to consistent supply to customers and commercialization success. Cosette has corporate and manufacturing facilities in New Jersey and North Carolina and is supported by more than 300+ dedicated employees across all functional areas. Cosette is backed by Avista Capital Partners, a healthcare focused private equity firm. www.cosettepharma.com

Follow us on LinkedIn.

Contacts

Serge Ilin-Schneider: bd@cosettepharma.com
Kian Kazemi: sales@cosettepharma.com

Cosette Pharmaceuticals, Inc.

Details
Headquarters: Bridgewater, New Jersey, USA
CEO: Apurva Saraf
Employees: 350
Organization: PRI

Release Versions

Contacts

Serge Ilin-Schneider: bd@cosettepharma.com
Kian Kazemi: sales@cosettepharma.com

Social Media Profiles
More News From Cosette Pharmaceuticals, Inc.

Cosette Pharmaceuticals Appoints Jeff Neubig as Vice President, Quality and Regulatory Affairs

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc., a U.S.-based, fully integrated, pharmaceutical company, announced today that it has appointed Jeff Neubig as Vice President, Quality and Regulatory Affairs. In this critical role, Jeff will lead Cosette’s best-in-class quality and regulatory affairs organizations, maintaining the company’s rigorous quality standards and further establishing Cosette’s strong position as a respected and reliable supplier of high-quality medicines....

Cosette Pharmaceuticals Announces Acquisition of Mayne Pharma, Transforming Company into a Leader in Women’s Health and Dermatology

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc., a U.S.-based, fully integrated, pharmaceutical company, announced today that it has entered into a definitive agreement to acquire all the outstanding shares of Mayne Pharma Group Limited (ASX: Ticker MYX) (Mayne Pharma) at AUD$7.40/share for a total consideration of approximately USD $430 Million. The Boards of Directors of both companies have approved the transaction and Mayne Pharma’s Board of Directors has unanimously recomm...

Cosette Pharmaceuticals Appoints Vincent Colicchio as Senior Vice President of Operations

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals Appoints Vincent Colicchio as Senior Vice President of Operations....
Back to Newsroom